We factored in Revenue/EBITDA/PAT CAGR of 27%/35%/52% over CY21-24E and arrive at a revised TP of Rs 1,300/share vs. Rs 1150/share earlier, valuing it at 36x Sep-24E EPS. Maintain BUY